ONCY Oncolytics Biotech, Inc.: רווח למניה אחת ב-12 החודשים האחרונים

Oncolytics Biotech Inc. (ONCY) is developing the innovative Pelareorep system, receiving regular payments from partners to maintain stability until it achieves positive cash flow. The uniqueness of this viral tumor treatment method opens prospects for high pricing power in the future. The asset's market dynamics based on EPS (TTM) stand at 2.00, while the company currently relies on research grants and future royalties from pharma behemoths.
Oncolytics Biotech Inc. - פילוחים אנליטיים ומדדי מפתח (ONCY)

For Oncolytics Biotech Inc. (ONCY), the trend in earnings per share reflects the efficiency of cost management amid inflationary pressures on the biotechnology sector. This metric calculates the percentage change in net income per share over the last twelve months relative to the same period last year. By analyzing this rolling year-over-year EPS chart, an investor assesses the business's ability to monetize its developments. A stable staff of Pelareorep experts provides the company with fundamental stability.